Stockwatch: Biggest companies were 2011's safest investment havens
This article was originally published in Scrip
Healthcare stocks were among the best performing in 2011, a turnaround from a disappointing 2010, with many of the leading names outpacing the general stock market indices by a large margin. Indeed, most of the major indices finished 2011 in negative territory, with the S&P 500 index closing some three thousandths of a percent down on the 2010 mark. The Dow Jones Industrial Average closed the year up 5.53%, while the technology-heavy NASDAQ Composite, which contains many biotech stocks, was down 1.8% on the year.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.